Close
Almac
Achema middle east

Why are decentralised clinical trials the future of the industry

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
- Advertisement -

Decentralized clinical trials (DCTs) can be considered to be the future of the industry due to the benefits they provide to drug developers and patients and their growing popularity. These benefits include ease for patients to participate in trials as they can do so remotely from home, as well as reducing the cost of research as less staff and resources are required as fewer patients visit trial sites.

Traditional clinical trials are often limited to studying diseases and conditions that are common enough to have a large number of patients available to participate. However DCTs can be used to study a wider range of diseases and conditions because they can reach a larger pool of patients, with more emerging rare diseases and small patient pools, the demand for DCTs will increase.

DCTs can help to accelerate the development of new treatments. Traditional clinical trials can take many years to complete. This is because they require a long time to recruit patients, collect data, and analyze the data. DCTs can help to accelerate the development of new treatments by reducing the time it takes to recruit patients and collect data.

DCTs can also help to improve patient recruitment and retention as studies have shown that patients are more likely to participate in DCTs than traditional clinical trials due to their flexibility and convenience.

Finally, DCTs can also help to improve patient safety. By using technology to collect data remotely, DCTs can provide researchers with real-time data on patient health. This data can be used to identify and address potential safety concerns as soon as possible.

For all of these reasons DCTs offer a number of advantages over traditional clinical trials. They have the potential be more efficient, effective, affordable, and patient-centred. Because of these reasons it is responsible to consider DCTs the future of clinical research as their limitations and the regulatory concerns will be addressed due to their growing popularity.

About Author

Claude Price, Vice President and Head of Clinical Data Management at Quanticate

 

 

 

 

Quanticate
Company Logo

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »